In Brief: Soberup warning letter
This article was originally published in The Tan Sheet
Soberup warning letter: Grand Junction, Colo.-based C&G Marketing and Manufacturing receives FDA warning letter Nov. 5 stating that the name and claims for the sobriety aid establish the product as an unapproved drug. Claims made in promotional fliers include: "Soberup...helps to detoxify alcohol from the system, which can help reduce its effects!" The product is subject to the final rule for overindulgence products, which says that no ingredient is safe and effective for use in an OTC drug either as a sobriety aid or to minimize or prevent inebriation, the warning letter notes. FDA requests that C&G immediately stop distribution of Soberup and notify the agency of the steps taken to correct the violations...
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC